Abstract
Introduction and objectivesHeterogeneity of idiopathic pulmonary fibrosis (IPF) means it is difficult to identify those at highest risk of progression who are most likely to benefit from treatment. A biomarker...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have